|
|
 |
| |
|
Home > Drug Companies > Amgen Inc
Amgen Inc
Amgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s lives.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.
Originally founded in 1980 as AMGen Applied Molecular Genetics, Amgen pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology.
Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives. In everything they do, they aim to fulfill that mission. And every step of the way, they are guided by the values that define them.
Aranesp is indicated for the treatment of anemia associated with chronic renal failure both in patients on dialysis and that not on dialysis, as well as for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies. It was approved in 2001 for patients with chronic renal failure, and in 2002 for the treatment of chemotherapy induced anemia.
The Amgen Nephrology Institute For 25 years, Amgen has been at the forefront of innovation in nephrology. Now, as part of their continuing commitment to advancing chronic kidney disease the CKD care, they are proud to introduce the Amgen Nephrology Institute.
At Amgen, they apply four guiding principles to their R&D efforts. The first is to focus on grievous illness. Given that it is so hard to succeed at developing a new therapy, they focus their efforts on developing therapies that have a beneficial effect on patients suffering from the greatest unmet medical needs.
Back to Drug Companies
|
|
|
|
|
|
|
|